Smart-Money SignalNeutral · 45/100— Insiders are net sellers over 90 days (-$1.3M, 10 sales vs 4 buys)
Revenue$71.5M
Net Income-$1.9M
EPS$-0.07
Market Cap$1.4B
Price Performance
Historical data including institutional events
Company Profile
J
John Shannon
CEO & Executive Director
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois.
It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushingâs syndrome.
It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism.
The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
